I am a board-certified hematologist/oncologist with a special interest in plasma cell dyscrasias — a group of disorders that includes multiple myeloma, amyloidosis, light chain deposition disease, POEMS syndrome, and Waldenström’s macroglobulinemia. There have been tremendous advances in this field over the past decade, and several new drugs are available or in development to manage these conditions. With my colleagues at Memorial Sloan Kettering Cancer Center, I have focused on developing and optimizing new approaches to treat these diseases, including both new drugs and new strategies to improve patients’ outcomes.
In multiple myeloma we currently have several clinical trials that are addressing important questions in patients who are newly diagnosed and have never been treated to better define the role and timing of autologous stem cell transplantation. We are also conducting several clinical trials in patients whose disease has recurred after initial treatment in order to develop new drugs that would be effective against the disease.
Likewise, in the field of amyloidosis and light chain deposition disease, we are currently testing the role of a comprehensive treatment that incorporates autologous stem cell transplantation preceded and followed by more conventional therapies. We are hopeful that this comprehensive treatment will allow optimal control of the disease.
I also have a particular interest in thrombotic complications (blood clotting) that occur in cancer patients and in patients receiving chemotherapy. We are trying to develop prophylactic strategies to decrease the frequency of these common complications in cancer patients using old and newer blood thinners.
- Clinical Expertise: Plasma Cell Dyscrasias: Multiple Myeloma; Amyloidosis; Light Chain deposition disease; Coagulation Disorders in Cancer Patients
- Languages Spoken: English
- Education: MD, University of Pierre et Marie Curie (Paris, France)
- Residencies: Brigham and Women's Hospital/Harvard Medical School
- Fellowships: St. Elizabeth's Medical Center/Tufts Medical School
- Board Certifications: Internal Medicine; Hematology/Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Hani Hassoun
- A Phase I/II Study of Pomalidomide and Dexamethasone with and without Ixazomib in Patients with Recurrent Multiple Myeloma
- A Phase II Study of Bortezomib/Dexamethasone Followed by Lenalidomide in Nonresponders as Initial Treatment for Multiple Myeloma
- A Phase II Study of Lenalidomide and Low-Dose Dexamethasone (LD) Followed by Continued LD or Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
- A Phase III Study of Lenalidomide, Bortezomib, and Dexamethasone Combination Treatment with or without Peripheral Stem Cell Transplantation in the Initial Management of Multiple Myeloma
Clinical Trials Co-Investigated by Hani Hassoun
- A Phase I Study of Carfilzomib in Patients with Previously Treated Systemic Light Chain Amyloidosis
- A Phase I Study of NEOD001 in Patients with Light Chain Amyloidosis
- A Phase II Study of Bendamustine and Dexamethasone in Patients with Relapsed Amyloidosis
- A Phase II Study of Pomalidomide plus Autologous Stem Cell Transplantation versus Pomalidomide/Dexamethasone in Patients with Multiple Myeloma
- A Phase III Study of Dexamethasone plus Ixazomib (MLN9708) or Standard Therapy in Patients with Recurrent or Persistent Systemic Light Chain Amyloidosis